KR20140093291A - ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 - Google Patents

ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 Download PDF

Info

Publication number
KR20140093291A
KR20140093291A KR1020147017714A KR20147017714A KR20140093291A KR 20140093291 A KR20140093291 A KR 20140093291A KR 1020147017714 A KR1020147017714 A KR 1020147017714A KR 20147017714 A KR20147017714 A KR 20147017714A KR 20140093291 A KR20140093291 A KR 20140093291A
Authority
KR
South Korea
Prior art keywords
methyl
mmol
alkyl
cyclopenta
dihydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020147017714A
Other languages
English (en)
Korean (ko)
Inventor
이안 에스. 미첼
제임스 에프. 블레이크
루이 수
니콜라스 씨. 켈런
덩밍 씨아오
키스 리 스펜서
조우지프 알. 벤칙
준 리앙
브라이언 사피나
비롱 장
크리스틴 샤보트
스티븐 두
엘리 엠. 월리스
애너 엘. 밴카
스티븐 티. 슐라츠터
Original Assignee
어레이 바이오파마 인크.
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140093291(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 어레이 바이오파마 인크., 제넨테크, 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20140093291A publication Critical patent/KR20140093291A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
KR1020147017714A 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘 Ceased KR20140093291A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81871806P 2006-07-06 2006-07-06
US60/818,718 2006-07-06
PCT/US2007/072885 WO2008006040A1 (en) 2006-07-06 2007-07-05 Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020137031899A Division KR101578877B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010625A Division KR20150051240A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Publications (1)

Publication Number Publication Date
KR20140093291A true KR20140093291A (ko) 2014-07-25

Family

ID=38686743

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020147017714A Ceased KR20140093291A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020157010625A Ceased KR20150051240A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020097002395A Active KR101178672B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020137031899A Active KR101578877B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020127011042A Active KR101495408B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020157010625A Ceased KR20150051240A (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020097002395A Active KR101178672B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020137031899A Active KR101578877B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR1020127011042A Active KR101495408B1 (ko) 2006-07-06 2007-07-05 ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘

Country Status (34)

Country Link
EP (4) EP2402325B1 (enExample)
JP (4) JP5266216B2 (enExample)
KR (5) KR20140093291A (enExample)
CN (2) CN102816124A (enExample)
AR (3) AR061842A1 (enExample)
AT (1) ATE524447T1 (enExample)
AU (1) AU2007269060B2 (enExample)
BR (3) BRPI0713923B8 (enExample)
CA (2) CA2836316A1 (enExample)
CL (1) CL2007001993A1 (enExample)
CO (1) CO6150161A2 (enExample)
CR (1) CR10600A (enExample)
CY (1) CY1112117T1 (enExample)
DK (2) DK2049501T3 (enExample)
ES (3) ES2554228T3 (enExample)
HR (1) HRP20110908T1 (enExample)
HU (1) HUE026237T2 (enExample)
IL (2) IL196028A (enExample)
IN (1) IN2014KN02886A (enExample)
MA (1) MA31655B1 (enExample)
MX (4) MX2008016202A (enExample)
MY (1) MY147364A (enExample)
NO (1) NO342346B1 (enExample)
NZ (3) NZ610633A (enExample)
PL (2) PL2402325T3 (enExample)
PT (1) PT2049501E (enExample)
RS (1) RS52212B (enExample)
RU (2) RU2478632C2 (enExample)
SG (4) SG184706A1 (enExample)
SI (2) SI2049501T1 (enExample)
TW (2) TWI402266B (enExample)
UA (1) UA95641C2 (enExample)
WO (1) WO2008006040A1 (enExample)
ZA (1) ZA200900070B (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602007011628D1 (de) * 2006-07-06 2011-02-10 Array Biopharma Inc Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren
EP2054418B1 (en) 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors
CA2656618C (en) 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
WO2008115511A1 (en) 2007-03-20 2008-09-25 Peak Biosciences, Inc. Method for therapeutic administration of radionucleosides
ES2533557T3 (es) 2007-07-05 2015-04-13 Array Biopharma, Inc. Pirimidil ciclopentanos como inhibidores de proteína cinasa AKT
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
AR067413A1 (es) 2007-07-05 2009-10-07 Genentech Inc Compuestos heterociclicos que contienen ciclopenta[d]pirimidina inhibidores de proteinquinasas akt, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de las mismas para el tratamiento de enfermedades hiperproliferativas, tales como cancer
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MX2010007546A (es) * 2008-01-09 2010-09-30 Array Biopharma Inc Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa.
CA2711782C (en) 2008-01-09 2017-01-03 Array Biopharma Inc. 5h-cyclopenta[d]pyrimidines as akt protein kinase inhibitors
WO2009089459A1 (en) 2008-01-09 2009-07-16 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors
US8324221B2 (en) 2008-01-09 2012-12-04 Array Biopharma Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
JP2014507129A (ja) * 2010-12-23 2014-03-27 ジェネンテック， インコーポレイテッド 腫瘍の治療のためのオートファジー誘導剤及び阻害剤の併用療法
CN103841976A (zh) * 2011-04-01 2014-06-04 基因泰克公司 Akt和mek抑制剂化合物的组合及其使用方法
CN103858007B (zh) * 2011-04-01 2017-03-29 基因泰克公司 用于预测对癌症治疗的敏感性的生物标记
CN103841975A (zh) 2011-04-01 2014-06-04 基因泰克公司 Akt抑制剂化合物和厄洛替尼的组合以及使用方法
MX354373B (es) * 2012-05-17 2018-02-28 Genentech Inc Proceso para hacer compuestos de ciclopentapirimidina hidroxilada y sus sales.
RS60417B9 (sr) 2012-05-17 2021-07-30 Genentech Inc Amorfni oblik aktivnog jedinjenja koje inhibira pirimidinil-ciklopentansko jedinjenje, smeše i njegove metode
JP6284928B2 (ja) 2012-05-17 2018-02-28 アレイ バイオファーマ、インコーポレイテッド ヒドロキシル化シクロペンチルピリミジン化合物を作製するためのプロセス
NZ702939A (en) * 2012-05-17 2016-08-26 Genentech Inc Process for making amino acid compounds
DK2861583T3 (en) 2012-05-17 2016-10-03 Array Biopharma Inc METHOD OF PRODUCING hydroxylated CYCLOPENTYLPYRIMIDINFORBINDELSER
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
MX2015007054A (es) 2012-12-07 2016-01-12 Gen Hospital Corp Combinaciones de un compuesto inhibidor de pi3k/akt con un compuesto inhibidor de her3/egfr, y métodos de uso.
JP6340162B2 (ja) 2012-12-20 2018-06-06 日東電工株式会社 アポトーシス誘導剤
SG10201901578UA (en) 2013-11-15 2019-03-28 Hoffmann La Roche Processes for the preparation of pyrimidinylcyclopentane compounds
US10457648B2 (en) * 2014-09-26 2019-10-29 Genentech Inc. Process for preparing (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
KR20250023595A (ko) 2016-08-10 2025-02-18 에프. 호프만-라 로슈 아게 Akt 단백질 키나아제 저해제를 포함하는 약학 조성물
JP2019537585A (ja) 2016-10-28 2019-12-26 アイカーン スクール オブ メディスン アット マウント シナイ Ｅｚｈ２媒介性がんを治療するための組成物および方法
US11472799B2 (en) * 2018-03-06 2022-10-18 Icahn School Of Medicine At Mount Sinai Serine threonine kinase (AKT) degradation / disruption compounds and methods of use
JP2021527666A (ja) 2018-06-21 2021-10-14 アイカーン スクール オブ メディスン アット マウント シナイ Ｗｄ４０反復ドメインタンパク質５（ｗｄｒ５）分解／破壊化合物および使用の方法
EP3897612A1 (en) 2018-12-19 2021-10-27 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
PL3919491T3 (pl) 2019-01-29 2025-10-20 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Inhibitor akt
EP3946330A1 (en) 2019-03-29 2022-02-09 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
EP3952871A4 (en) * 2019-04-09 2023-06-07 Dana-Farber Cancer Institute, Inc. AKT DEGRADATION BY CONJUGATION OF ATP COMPETITIVE AKT INHIBITOR GDC-0068 WITH E3 LIGASE LIGANDS AND METHODS OF USE
CN114423463B (zh) 2019-05-06 2025-09-26 西奈山伊坎医学院 作为hpk1的降解剂的异双功能化合物
KR20220154722A (ko) * 2020-03-17 2022-11-22 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 융합된 이환식 유도체, 이의 제조 방법, 및 이의 약학적 용도
US12103924B2 (en) 2020-06-01 2024-10-01 Icahn School Of Medicine At Mount Sinai Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use
IL295929A (en) 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
WO2022017449A1 (zh) 2020-07-22 2022-01-27 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮衍生物的盐、其制备方法及用途
TWI750905B (zh) * 2020-11-19 2021-12-21 財團法人國家衛生研究院 噻唑化合物作為蛋白質激酶抑制劑
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
WO2023043869A1 (en) * 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate
CN113788834B (zh) * 2021-09-18 2022-11-29 河南奥思恩医药科技有限公司 2,4-二氯-6,7-二氢-5H-吡咯并[3,4-d]嘧啶盐酸盐的制备方法
WO2023109540A1 (zh) * 2021-12-17 2023-06-22 中国医药研究开发中心有限公司 具有akt激酶抑制活性的杂环化合物及其制备方法和医药用途
CN119278041A (zh) 2022-03-31 2025-01-07 阿斯利康(瑞典)有限公司 用于治疗癌症的与akt抑制剂组合的表皮生长因子受体（egfr）酪氨酸激酶抑制剂
IL320302A (en) 2022-10-17 2025-06-01 Astrazeneca Ab SERD combinations for cancer treatment
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
WO2024160843A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Mutant ketoreductase with increased ketoreductase activity as well as methods and uses involving the same
EP4643858A1 (en) 2024-04-29 2025-11-05 Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical composition for the treatment of uterine disease

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NL7112938A (enExample) * 1970-09-30 1972-04-05
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2276098C (en) * 1997-01-08 2007-05-08 F. Hoffmann-La Roche Ag Tricyclic benzo[e]isoindoles and benzo[h]isoquinolines
ES2152902B1 (es) * 1999-07-27 2001-08-16 Medichem Sa Procedimiento de obtencion de venlafaxina
EP2277877A1 (en) * 2000-08-18 2011-01-26 Millennium Pharmaceuticals, Inc. Quinazoline derivatives as kinase inhibitors
DK1318997T3 (da) * 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
MXPA03008936A (es) * 2001-03-30 2005-03-07 King Pharmaceuticals Res & Dev Compuestos farmaceuticamente activos y metodos de uso.
JP4391825B2 (ja) * 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
MXPA04007191A (es) * 2002-01-23 2005-03-31 Bayer Pharmaceuticals Corp Derivados de pirimidina como inhibidores de rho-quinasa.
TW200306819A (en) * 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1684694A2 (en) * 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
DE602005020611D1 (de) * 2004-04-28 2010-05-27 Vertex Pharma Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
WO2006094230A2 (en) * 2005-03-03 2006-09-08 The Burnham Institute For Medical Research Screening methods for protein kinase b inhibitors employing virtual docking approaches and compounds and compositions discovered thereby
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
CA2656618C (en) * 2006-07-06 2014-08-26 Array Biopharma Inc. Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
EP2054418B1 (en) * 2006-07-06 2011-11-09 Array Biopharma Inc. Dihydrothieno pyrimidines as akt protein kinase inhibitors

Also Published As

Publication number Publication date
RU2009103900A (ru) 2010-08-20
CO6150161A2 (es) 2010-04-20
MX2019008117A (es) 2019-09-04
CA2656622C (en) 2017-09-12
MY147364A (en) 2012-11-30
DK2049501T3 (da) 2011-12-12
SI2402325T1 (sl) 2015-12-31
AR093810A2 (es) 2015-06-24
HRP20110908T1 (hr) 2012-02-29
IL241705A0 (en) 2015-11-30
EP2966065A3 (en) 2016-03-02
NO20090581L (no) 2009-04-06
KR20090030333A (ko) 2009-03-24
SG10201802127UA (en) 2018-04-27
IN2014KN02886A (enExample) 2015-05-08
HUE026237T2 (en) 2016-06-28
HK1160638A1 (en) 2012-08-10
WO2008006040A1 (en) 2008-01-10
JP2014231530A (ja) 2014-12-11
ES2554252T3 (es) 2015-12-17
CN101578273A (zh) 2009-11-11
KR20130029364A (ko) 2013-03-22
EP2402325B1 (en) 2015-08-26
PT2049501E (pt) 2011-12-30
KR20150051240A (ko) 2015-05-11
BRPI0713923B8 (pt) 2021-05-25
IL196028A (en) 2017-02-28
JP2009542723A (ja) 2009-12-03
RU2478632C2 (ru) 2013-04-10
EP2049501A1 (en) 2009-04-22
JP5266216B2 (ja) 2013-08-21
EP2399909B1 (en) 2015-08-26
NZ597647A (en) 2013-08-30
RS52212B (sr) 2012-10-31
CN101578273B (zh) 2012-11-14
SI2049501T1 (sl) 2012-01-31
IL196028A0 (en) 2009-09-01
MX377920B (es) 2025-03-11
BR122013028005B1 (pt) 2021-04-06
NO342346B1 (no) 2018-05-07
CY1112117T1 (el) 2015-11-04
BRPI0713923A2 (pt) 2013-07-02
JP5836294B2 (ja) 2015-12-24
TW201332994A (zh) 2013-08-16
NZ610633A (en) 2014-12-24
JP2013177470A (ja) 2013-09-09
KR101178672B1 (ko) 2012-09-07
NZ573732A (en) 2012-03-30
MX337843B (es) 2016-03-22
CL2007001993A1 (es) 2008-06-20
BR122013028012B8 (pt) 2021-05-25
HK1160134A1 (en) 2012-08-10
AR061842A1 (es) 2008-09-24
DK2402325T3 (en) 2015-12-07
HK1126768A1 (en) 2009-09-11
RU2012155606A (ru) 2014-06-27
MX366319B (es) 2019-07-05
MA31655B1 (fr) 2010-09-01
EP2399909A1 (en) 2011-12-28
ES2372774T3 (es) 2012-01-26
ES2554228T3 (es) 2015-12-17
TW200817373A (en) 2008-04-16
AU2007269060B2 (en) 2014-02-20
PL2049501T3 (pl) 2012-02-29
PL2402325T3 (pl) 2016-01-29
ATE524447T1 (de) 2011-09-15
BR122013028005B8 (pt) 2021-05-25
KR101578877B1 (ko) 2016-02-22
BRPI0713923B1 (pt) 2020-09-29
CA2836316A1 (en) 2008-01-10
MX2008016202A (es) 2009-02-11
AR109424A2 (es) 2018-11-28
KR20130141717A (ko) 2013-12-26
CA2656622A1 (en) 2008-01-10
KR101495408B1 (ko) 2015-02-25
EP2966065A2 (en) 2016-01-13
SG184706A1 (en) 2012-10-30
SG188905A1 (en) 2013-04-30
EP2402325A3 (en) 2012-06-13
TWI402266B (zh) 2013-07-21
JP2013091670A (ja) 2013-05-16
CR10600A (es) 2009-02-20
AU2007269060A1 (en) 2008-01-10
ZA200900070B (en) 2010-03-31
SG185980A1 (en) 2012-12-28
CN102816124A (zh) 2012-12-12
EP2049501B1 (en) 2011-09-14
BR122013028012B1 (pt) 2021-04-06
UA95641C2 (xx) 2011-08-25
EP2402325A2 (en) 2012-01-04

Similar Documents

Publication Publication Date Title
KR101495408B1 (ko) ＡＫＴ 단백질 키나제 억제제로서의 히드록실화 및 메톡실화 시클로펜타［ｄ］피리미딘
KR101527232B1 (ko) Ａｋｔ 단백질 키나제 억제제로서의 시클로펜타〔ｄ〕피리미딘
US8063050B2 (en) Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
JP5231410B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロフロピリミジン
JP5231411B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのジヒドロチエノピリミジン
JP5542282B2 (ja) Ａｋｔプロテインキナーゼ阻害剤としてのピリミジルシクロペンタン
KR20100044819A (ko) Ａｋｔ 단백질 키나제 억제제로서의 피리미딜 시클로펜탄
US9409886B2 (en) Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
HK1176072A (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20140626

Application number text: 1020137031899

Filing date: 20131129

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140725

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141023

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150423

Application number text: 1020137031899

Filing date: 20131129

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150521

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141023

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20150527

WITB Written withdrawal of application